1 Title

2	"A Randomized Placebo Controlled Clinical Trial of a Metabolic Shifting Probiotic,
3	Sugar Shift, for the Treatment of T2DM"
4	Authors: Gissel García ^{1a} , Josanne Soto ^{1b} , Lays Rodríguez ^{1c} , Maricela Nuez ^{1d} , Noraika
5	Domínguez ^{1d} , Emilio F. Buchaca ^{1c} , Duniesky Martínez ² , Rolando J. Gómez ^{1b} ,
6	Yohanka Ávila ¹ , Martha R. Carlin ³ , Raúl J. Cano ^{3, 4*} .
7	Affiliations:
8	^{1a} Pathology Department, Clinical Hospital Hermanos Ameijeiras (HHA). Calle San
9	Lázaro No 701, Esq.a Belascoaín, Centro Habana, La Habana, P.C. 10400, Cuba.
10	^{1b} Clinical Laboratory Department, Clinical Hospital Hermanos Ameijeiras (HHA). Calle
11	San Lázaro No 701, Esq.a Belascoaín, Centro Habana, La Habana, P.C. 10400, Cuba.
12	^{1c} Internal Medicine Department, Clinical Hospital Hermanos Ameijeiras (HHA). Calle
13	San Lázaro No 701, Esq. a Belascoaín, Centro Habana, La Habana, P.C. 10400, Cuba.
14	^{1d} Endocrinology Department, Clinical Hospital Hermanos Ameijeiras (HHA). Calle San
15	Lázaro No 701, Esq.a Belascoaín, Centro Habana, La Habana, P.C. 10400, Cuba.
16	² Research and Development Department. Center for Genetic Engineering and
17	Biotechnology of Sancti Spíritus (CIGBSS),. Circunvalante Norte S/N, Olivos 3,
18	Apartado Postal 83, Sancti Spíritus, P.C 60200, Cuba.
19	³ The BioCollective, LLC, 5650 N. Washington St, Suite C9, Denver, Co 80216

- 20 ⁴ Biological Sciences Department, California Polytechnic State University, San Luis
- 21 Obispo, CA 93407 USA
- 22
- 23 *Corresponding author and address: 1854 Castillo Court, San Luis Obispo, CA 93405
- 24 USA;
- 25 Tel: +1 (805) 748-9717; E-mail: rcano@calpoly.edu
- 26

27 Abstract

28 Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by 29 hyperglycemia, insulin resistance and chronic inflammation. Probiotics have been 30 claimed effective in the management of obesity and type 2 diabetes mellitus. 31 BiotiQuest[™] Sugar Shift is a symbiotic formulation rationally designed for the 32 endogenous conversion of glucose and fructose to support restoration of the human 33 gut microbiota, modulation of intestinal glucose, and the production of anti-34 inflammatory metabolites. 35 We report the results of a 12-week, double blind, placebo-controlled study designed to 36 evaluate Sugar Shift in Cuban T2DM patients. Clinical parameters, including fasting 37 and 2h post-prandial glucose, hemoglobin A1c, a lipid panel, insulin, creatinine, and 38 serum lipopolysaccharide levels were assessed. Microbiome composition was 39 assessed by 16S amplicon sequencing of the variable region V3-V4 of the 16S rRNA 40 gene. Metabolic biomarkers were inferred from microbiome data by Kruskal-Wallis H 41 test and LEfSe. 42 Fasting glucose, Insulin, and serum LPS levels decreased significantly at day 84 as 43 compared to day 1 in the treated group and to control group. Hb A1c remained stable 44 in the treatment group as compared to the controls but not show significant 45 improvement in the study period. 46 Microbiome analysis showed significant increase in Chao1 alpha diversity in the 47 treated group between day 1 and day 84. Taxonomic and functional biomarkers

48 revealed significant differences between the Day 1 and Day 84 microbiome profiles in

- 49 the treatment group, primarily associated with acetate, propionate, and butyrate50 production.
- 51 Our results indicate that Sugar Shift can be a suitable adjunct therapy to standard of
- 52 care therapy in the management of T2DM based upon the improvement in key
- 53 inflammatory and insulin resistance markers. These results were interpreted as an
- 54 indication of favorable microbiome changes during the course of the treatment for 12
- 55 weeks.
- 56

57 Introduction

58 Diabetes mellitus (DM), is a metabolic disease characterized by alterations in glucose 59 metabolism (1). Four main etiological categories are described: type 1 (T1DM), type 2 60 (T2DM), seasonal DM and the other types of DM, which fall into the same etiological 61 category. T2DM comprises 90% of all cases (1). Statistics from 2018 show that this 62 metabolic condition affected 537 million individuals worldwide 63 (https://idf.org/aboutdiabetes/what-is-diabetes/facts-figures.html) and it is estimated 64 that by 2045, about 625 million people will suffer from this disease (2). Cuba does not 65 escape this situation; in the Statistical Yearbook of the Ministry of Public Health (MINSAP) of 2019, a prevalence of this disease of 66.7% was reported, 2% higher than 66 67 that reported in 2018 (3). Therefore, diabetes mellitus in general, and type 2 in 68 particular, is considered an emerging pandemic disease by the international scientific community, since its prevalence increases in all countries regardless of their level of 69 70 development (4). 71 T2DM is diagnosed when there is a state of glucose intolerance (glucose \geq 72 11.1mmol/L) and fasting elevated blood sugar levels (≥ 7mmol/L or126 mg/dl) are 73 detectable. (1, 5). Treatment requires lifestyle change, timely incorporation of oral 74 antidiabetics, including metformin, and maintaining of glycosylated hemoglobin

75 (HbA1c) at levels below 7%. However, in clinical practice, patients do not always

76 achieve glycemic control (4).

It is proposed that genetic and environmental factors are associated with the
development of this etiological category (1, 6). In the context of these factors, the gut

microbiota plays a central role in this disease as it is able to modify the biological and
metabolic functions of the organism, regulate inflammation and as is essential for the
mechanisms of innate and adaptive immunity (7).

82 Disease severity, immunodeficiencies, obesity and insulin resistance have been 83 associated with imbalances in the gut microbiota. This phenomenon, known as 84 dysbiosis, occurs from multiple causes (4). These include unbalanced diets (8), 85 environmental toxin exposures (9, 10) and the indiscriminate use of antibiotics (11, 12), 86 among other factors that have been associated with the pathogenesis of T2DM (13-87 15). A diet rich in carbohydrates and processed foods favors the reduction of beneficial 88 bacteria and the growth of others that, for example, increase the secretion of 89 lipopolysaccharides (LPS). Increased secretion of LPS induces insulin resistance (1, 4, 90 7).

91 Recent studies support that the consumption of certain formulations of beneficial 92 bacteria in association with the nutrients they produce could reshape the intestinal 93 microbiota and, in this way, improve glucose levels and insulin resistance in individuals 94 suffering from T2DM (16). This group of living microorganisms, administered to a host 95 in appropriate forms and quantities, improves or restores the intestinal microbiota and, 96 consequently, its metabolic and immunological functions. For this reason, these 97 organisms have been referred to as probiotics. These mixtures are administered as a 98 symbiotic formulation with prebiotics and non-digestible plant fibers that stimulate the 99 growth of the probiotic organisms and other beneficial intestinal microorganisms (16, 100 17).

6

101 There are many commercial probiotic formulations on the market which mostly 102 comprise a limited variety of commercial probiotic strains in wide use. However, many 103 are not balanced formulations and there is very little strain or species diversity in the 104 currently commercialized products. Many formulas do not contain any prebiotic at all 105 and most do not evaluate or show the analysis of the genetic and metabolic profile of 106 the consortium of bacteria as a working community in the formula. The BiotiQuest™ 107 Sugar Shift (Sugar Shift) preparation, on the other hand, is a formulation designed with 108 the aid of a community-based flux balance analysis model (18, 19), coined the 109 BioFlux[™] model, an in silico analytical platform for modeling microbial consortia. The 110 computational modeling provides for the design of formulations with a balance of the 111 flow of metabolic inputs and outputs over time to target a specific metabolic output 112 and improved sustainability. The symbiotic formulation Sugar Shift consists of eight 113 strains of bacteria with GRAS (Generally Recognized as Safe) classification. The core 114 properties of this formula's design are the production of mannitol, with the concomitant 115 reduction of glucose and fructose, the production of anti-inflammatory components, 116 such as butyrate (20) and the antioxidant reduced glutathione (21).

This study was designed to determine whether Sugar Shift would be an effective adjunct therapy to the prevailing standard of care to T2DM. This study was designed as a double blind, placebo-controlled study aimed to evaluate the supplement Sugar Shift in a population of Cuban T2DM patients during the course of 12 weeks. This decision for the venue was made based on the excellence of the National Health System in Cuba and the track record in well-conducted clinical trials (22) as well as on the reports indicating that the epidemiology of T2DM in Cuba is similar to that of therest of the world (3).

125 Hypothesis

126 T2DM is a chronic metabolic disorder characterized by hyperglycemia, insulin

127 resistance and chronic inflammation (23). Several studies have reported gut

128 microbiome dysbiosis as a factor in rapid progression of insulin resistance in T2DM

129 that accounts for about 90% of all diabetes cases worldwide (1). Probiotics, prebiotics,

130 symbiotics, and postbiotics benefit metabolic diseases management, especially

131 obesity and type 2 diabetes mellitus (24). Sugar Shift is a symbiotic formulation

132 rationally designed for the conversion of glucose and fructose to support restoration of

133 the human gut microbiota, the modulation of intestinal glucose, and the production of

134 anti-inflammatory metabolites and therefore stabilize blood glucose, improve insulin

135 resistance, and reduce inflammation.

136

137 Materials and Methods

138 Study design

139 The study was designed and conducted as a randomized and double blind, placebo-

140 controlled trial to investigate the effect of Sugar Shift as a supplementary therapeutic

- 141 approach for T2DM with ISRCTN registry number ISRCTN48974890. The full trial
- 142 protocol is provided herein as supplementary material, including the English translation

- 143 of the approved document submitted to the Institutional Review Board for approval.
- 144 The CONSORT flowchart of the study is shown in Fig 1.

145	Fig 1. CONSORT 2010 Flowchart of the Study
146	
147	The study was conducted at Hermanos Ameijeiras Clinical Hospital, an Academic
148	Medical Center in La Habana, Cuba. Fig 2 show outlines the study design and timeline.
149	No changes to the approved protocol by the Institutional Review Boards were made.
150 151	Fig. 2. Schematic representation of the clinical study design.
152	The diagram represents the various elements and metrics used in the present study.
153	The Purple zone, representing the enrollment period, extended for more than 6 months,
154	until the number of participants exceeded the minimum required to achieve the power
155	of 0.8. The clinical study, represented by the blue bar, extended for exactly 12 weeks,
156	while the Analysis period (green bar) extended for more than 4 weeks. The boxes
157	contain the assays performed at the time periods indicated (in weeks) in the diagram
158	Ethical Considerations
159	This trial was evaluated and approved under the Hermanos Ameijeiras Ethic Committee
160	for Clinical Investigation and The Hermanos Ameijeiras Scientific Council. The Sugar
161	Shift Probiotic supplements were also evaluated and approved for their use by the
162	Ethical Committee at the National Institute of Nutrition of Cuba and The Cuba Ministry

163 of Health. The study was conducted considering the Good Clinical Practice and in

accordance with the code of ethics of the World Medical Association Declaration ofHelsinki (25).

166 Eligibility

All patients diagnosed with T2DM (26) between 30 and 65 years old and body mass index (BMI between 28-40) at baseline, who attended the diabetes specialized consultations of the Hermanos Ameijeiras Hospital and who gave their consent to participate in the study, without excluding sex or skin color, were selected. Patients with chronic kidney disease, onco-proliferative diseases and pregnant women were excluded.

173 Power and sample size consideration

174 The sample size was estimated with a two-sided alpha of 0.05, 95% confidence level,

175 standardized mean difference of 0.75, test power of 80%, expected proportion of

176 losses of 10%. Based on this information, the minimum required sample size was

177 estimated to be 28 individuals per group; adjusted for losses for various reasons, the

178 sample size was established at 32. The sample consisted of 64 patients who

179 consented to participate in the research.

180 Patients Recruitment

181 The recruitment period of the patients was from June 2021 to April 2022. The period

182 was extended due to Covid and lockdown. Patients were surveyed according to the

183 inclusion criteria and the discretion of the attending physician for inclusion in the study,

also we ask for information if the patients had had SARS-CoV-2 infection.

185 Randomization

186 The included patients were assigned to two treatment groups by randomization 187 technique: Group A (Sugar Shift) consisted of 32 patients who were assigned to the 188 treatment group, Group B (control): consisted of 32 patients who were given a placebo. 189 Assignment to treatment groups was randomized using the Epidemiological Analysis 190 from Tabulated Data (EpiData 3.1) software (http://www.epidata.dk). The list of random 191 numbers for each group was placed in the pharmacy. The assignment was made when 192 the patient's compliance with the inclusion and signature criteria for the informed 193 consent to participate in the study was verified. The products were dispensed by a 194 pharmacist who distributed a corresponding number of capsules to each patient, 195 according to the order of arrival at the pharmacy and this was noted in the medical 196 record. Both Sugar Shift and placebo were packaged in indistinguishable foil 197 packaging as well as same size capsules to maintain blinding. Subjects may be 198 unblinded if deemed medically necessary by their provider and the study principal 199 investigator (PI) in Cuba. However, in this study no subjects were unblinded.

200 Delimitation and operationalization of variables

- 201 The variables measured in this study were as follows: age (in years completed); sex
- 202 (female, male); nutritional evaluation (according to body mass index (BMI) = Weight in
- 203 Kg / Height in m²: low weight: < 18.5 Kg/m², normal weight: 18.5-24.9 Kg/m²,
- 204 overweight: 25-29.9 Kg/m², obesity: \geq 30 Kg/m².
- 205 The Primary response variable was hemoglobin A1c (HbA1c) (%). The Secondary
- 206 Response Variables were fasting glucose (FBG) (mmol/L), postprandial glucose (PPG) -

- 207 2h (mmol/L), insulin (mU/mL); total cholesterol (mmol/L), triglycerides (mmol/L), high
- 208 density lipoprotein (HDL-c) (mmol/L), low density lipoprotein (LDL-c) (mmol/L) and
- 209 lipopolysaccharide (LPS) levels determination mml/L).

210 Trial intervention

- 211 Subjects consumed Sugar Shift or placebo (Control Group) daily, two capsules per
- 212 day, 12 hours apart. The foil packaging containing the capsules were distributed every
- 213 28 days over the 12-week study period after blood sample collection for clinical
- 214 determination (Visit 1, Visit 28 and Visit 56 as timeline shown in Fig 1).

215 Test substance

- 216 The "test substance", Sugar Shift was manufactured by BlisterPak Pro, LLC (Lafayette,
- 217 Colorado). Each capsule contains 96 mg (18 billion CFU) of a bacterial consortium of
- eight strains of GRAS-classified bacteria that include *Bacillus subtilis* De111[™],
- 219 Bifidobacterium bifidum, Bifidobacterium longum, Lactobacillus paracasei,
- 220 Lactobacillus plantarum TBC0036, Lactobacillus reuteri, Leuconostoc mesenteroides
- TBC0037, and *Pediococcus acidilactici*. Each capsule contains 370 mg of prebiotics
- and fillers consisting of inulin, microcrystalline cellulose, D-mannitol, and stearic acid.

223 Placebo control

- 224 The capsules, indistinguishable in appearance from the test substance, were similarly
- 225 manufactured by BlisterPak Pro, LLC (Lafayette, Colorado) and contained the same
- ingredients in identical proportions as the test substance sans the microbial

227 consortium. Each placebo capsule contained 50 mg each of the prebiotics inulin and

228 D-mannitol and 270 of the fillers microcrystalline cellulose, and stearic acid.

229 Organization and sample collection

The patients, once randomized, were divided into subgroups for office visits to facilitate instruction and clinical evaluation of the participants as well as sample collection. Each group was cited every 28 days for sample collection and delivery of supplements and clinical evaluation. Fecal samples from ten patients from each cohort group were collected for microbiome characterization studies at Day 1 and Day 84 of the study (for a total of 40 fecal samples).

All patients included in the study were measured for: FBG, PPG, cholesterol,

237 triglycerides, HDLc, LDLc, HbA1c, LPS, and fasting insulin. To obtain the biological 238 samples, the patients were instructed to fast for 8 hours. Whole blood samples were 239 obtained by venipuncture. The serum was obtained after centrifugation of the primary 240 sample within 1 hour to 1 hour 30 minutes after extraction, to be processed and 241 aliquoted for preservation and subsequent use. The preservation of aliquots of fasting 242 samples was carried out in the containers intended for this purpose at a temperature -243 20 °C until used for LPS determination (Fig 1). The blood sample for the HbA1c 244 determination was dispensed in blood collection K3EDTA tubes (Henso Medical 245 (Hangzhou) Co., Ltd.).

To ensure data security, electronic records of subject data were maintained using a
dedicated Microsoft Excel Database, Access to electronic databases was password
protected and limited to study staff and clinical staff supporting the subject's care. The

Hermanos Ameijeiras Hospital managed the security and viability of the informationtechnology infrastructure

251 Adverse events (AE)

252 This was a minimal risk study that involved the use of a commercially available dietary

- supplement and AEs related to the study product beyond the potential for bloating or
- excessive gas if taken in excess (beyond recommended dosing) were not anticipated.
- 255 Creatinine levels were measured to assess, the impact, if any, on the kidney of the
- 256 participants in all study groups.

257 Clinical Determinations

- 258 The determinations were made in a modular immunochemical autoanalyzer Cobas
- 259 6000, from Roche Diagnostic that meets the requirements stipulated in Directive
- 260 98/79/EC of the European Parliament and the Council of the European Union (EU) on in
- 261 *vitro* diagnostic medical devices, following the Standard Operating Procedures (SOPs)
- in force, and with the quality standards required for them (Table 1).

263 LPS determination

- 264 The determinations of serum LPS levels (results expressed in Endotoxin Units) of
- 265 participating patients were made using the commercial kit ToxinSensor[™] Endotoxin
- 266 Detection System (Version 11242021), following the manufacturer's instructions
- 267 (www.genscript.com).
- 268

269 Table 1 Quality Standards used with the Immunochemical Autoanalyzer Cobas 6000

Paramenter	Range of Quality Control Standard
FBG	4.2 - 7 mmol/L
PPG	≤ 10 mmol/L
Cholesterol	3.6 – 5.2 mmol/L
Triglycerides	0.5 – 1.85 mmol/L
HDLc	≥ 0.9 mmol/L
LDLc	2.6 – 3.35 mmol/L
HbA1c	≤ 6%
Insulin	2.6 – 24.94 mIU/mL
Creatinine	47.6 – 113.4 µmol/L

270

271 Microbiome Analysis

272 Fecal samples were collected using DNA/RNA Shield[™] Fecal Collection Tubes (Zymo

273 Research, Irvine, CA) and stored at room temperature until processed.

274 *16S amplicon sequencing*

- 275 16S amplicon sequencing was performed by EzBiome (Gaithersburg, MD, USA).
- 276 Genomic DNA concentration was quantified using the Qubit fluorometer
- 277 (ThermoFisher, USA). The 16S rRNA V3-V4 regions within the ribosomal transcript were
- 278 amplified using the primer pair (Illumina-F: and Illumina-R, which contains the
- 279 gene-specific sequences and Illumina adapter overhang nucleotide sequences using
- 280 EzBiome's established protocol. It is noteworthy to indicate that microbiome reference
- 281 standards (ZymoBIOMICS Microbial Community Standard, Zymo Research, Irvine, CA)
- 282 were used to quality control the process.

283 Amplicon Taxonomic Assignment and Functional Prediction:

284 Taxonomic profiling of 16S sequencing data was carried out by directly uploading 285 forward and reverse paired end reads to the EzBioCloud microbiome taxonomy 286 profiling platform (www.ezbiocloud.net) as described elsewhere (27). Briefly, the cloud 287 application of the EzBioCloud detects and filter out sequences of low quality regarding 288 read length (<80bp or >2,000bp) and averaged Q values less than 25. Denoising and 289 extraction of non-redundant reads are carried out using DUDE-Seq software (28). The 290 UCHIME (29) algorithm is applied against the EzBioCloud 16S chimera-free database 291 to check and remove chimera sequencing. Taxonomic assignment is performed using 292 the USEARCH program (30) to detect and calculate the sequence similarities of the 293 guery single-end reads against the EzBioCloud 16S database. Sequencing reads are 294 clustered into OTUs at 97% sequence similarity using the UPARSE algorithm (31). 295 Reads from each sample were clustered into many OTUs using the UCLUST (32) tool 296 with the above-noted cutoff values. For the EzBioCloud 16S-based MTP pipeline, the 297 PICRUSt2 algorithm (33) was used to estimate the functional profiles of the 298 microbiome identified using 16S rRNA sequencing. The raw sequencing reads were 299 computed using the EzBioCloud 16S microbiome pipeline with default parameters and 300 discriminating reads that were encountered in the reference database. The functional 301 abundance profiles of the microbiome are annotated based on bioinformatics analyses, 302 specifically by multiplying the vector of gene counts for each OTU by the abundance of 303 that OTU in each sample, using the KEGG (Kyoto Encyclopedia of Genes and 304 Genomes) (34) orthology and pathway database.

305 Amplicon Comparative Statistical and Bioinformatic Analyses

306 Subsampling, generation of taxonomy plots/tables and rarefaction curves, and 307 calculation of species richness, coverage, and alpha and beta diversity indices were 308 carried out in EzBioCloud Application. Briefly, microbial richness was measured by 309 ACE, Chao1, Jackknife and the number of OTUs found in the microbiome taxonomic 310 profile (MTP) index. The Shannon, Simpson and Phylogenetic α-diversity indices were 311 applied to estimate the diversity for each group using the Wilcoxon rank-sum test (35). 312 Beta diversity was calculated with Bray-Curtis (36), UniFrac and Generalized UniFrac 313 (37) distances based on the taxonomic abundance profiles. Permutational multivariate 314 analysis of variance (PERMANOVA) (38) were applied to measure the statistical 315 significances of β -diversity. Different groups were clustered with principal component 316 analysis (PCoA) based on abundance Jaccard distance metric. Kruskal-Wallis H test 317 (39) and LEfSe (40, 41) analysis were performed to determine enrichment in the 318 assigned taxonomic and functional profiles between groups. Taxonomic levels with 319 LEfSe values higher than 2 at a p-value < 0.05 were considered statistically significant. 320 The ggplot2 package in the R program (version 3.4.3., R Foundation for Statistical 321 Computing, Vienna, Austria) were used to visualize the LEfSe differences between the 322 groups. All the calculated p values were two-tailed and considered statistically 323 significant at p<0.05.

324 Statistical analysis

325 *Clinical data*

326 The information collected was organized in an Excel database. These data were then

327 exported to the Statistical Package for Social Sciences (SPSS) version 23.0 system for

328 analysis and R For Windows - R: The R Project For Statistical Computing, version

4.2.0. Samples were characterized through the description of the variables of interest.

330 Qualitative variables were summarized in absolute numbers and percentages.

331 Quantitative variables were summarized in mean and standard deviation when data

332 presented a normal distribution, verified by the Kolmogorov-Smirnov test for normality

333 (42); if they did not present normal distribution, they were summarized in median and

334 interquartile range (IR).

To detect differences between the groups according to qualitative variables, the chisquare test (χ^2) (43) was used. For the same purpose, the Student's t-test (44) was applied in the case of age (quantitative variable).

338 The comparison of medians of the variables that provided information on the effect of

therapeutics between the different times (day 1, day 28, day 56 and day 84), was

340 performed using the Friedman test (45). In the case of the initial (day 1) and final (day

341 84) comparison, the Wilcoxon signed range test (46) was used.

342 The comparison of variance between both groups that provide information about of the

343 effect of probiotics therapeutics between the different times (day 1, day 28, day 56 and

day 84), was performed using the F-Test Two-Sample for Variances (47). Analysis of

345 covariance (ANCOVA) is a general lineal model which blends ANOVA and regression. 346 ANCOVA evaluates whether the means of a dependent variable (DV) are equal across 347 levels of a categorical independent variable (IV) often called a treatment, while 348 statistically controlling for the effect of other continuous variables that are not of 349 primary interest, known as covariates (CV) or nuisance variables. Mathematically, 350 ANCOVA decomposes the variance in the DV into variance explained by the 351 categorical IV, and residual variance. Intuitively, ANCOVA can be thought of as 352 adjusting" the DV by the group means of the CV (s) The ANCOVA model assumes a 353 linear relationship between the response (DV) and covariate. (CV) (48). We worked with 354 the level of significance $\alpha = 0.05$ in all hypothesis tests.

To detect differences according to quantitative LPS and insulin determinations between the groups and in the groups respect day 1 to day 84 the paired sample t-test was applied as well as Pearson's correlation (43). Also, the analysis assuming unequal variance was made to detect the differences between day 1 and day 84 at a level of significance $\alpha = 0.05$ to test the hypothesis.

360 *Microbiome data*

361 All statistical analyses were performed using packages 'vegan' v2.5-6, 'phyloseq',

362 'ggpubr' and 'ggplot2' v3.3.2 in R 3.6.3 (https://www.r-project.org/. For microbiome

- analysis, rarefaction depth was set at 25,000 reads. Shannon diversity index. (49),
- 364 Chao1 Index (50) and Good's Coverage of library (51) were used to evaluate alpha
- 365 (within sample) diversity. Beta (between sample) diversity was examined using
- 366 multidimensional scaling analysis (MDA) (52) of Bray-Curtis (36) and Jaccard (53)

367 distances. The Wilcoxon rank-sum test (35) was used to compare alpha diversity 368 values between groups (p > 0.05). Statistical significance of beta-diversity distances 369 between stool processing workflows was assessed using PERMANOVA (38) with 999 370 permutations. Alpha diversity group significance was calculated using nonparametric 371 Kruskal-Wallis H test (39). Taxonomic features descriptive of each cohort were 372 identified using Linear Discriminate Analysis (LDA) Effect Size (LEfSe) (40), employing 373 the Kruskal-Wallis (KW) sum-rank test (39) to detect features with significant differential 374 abundance with respect to the class of interest. The biological significance is then 375 investigated using a set of pairwise tests among subclasses using the (unpaired) 376 Wilcoxon rank-sum test (35). As a last step, LEfSe uses Linear Discriminant Analysis 377 (54) to estimate the effect size of each differentially abundant feature and, if desired by 378 the investigator, to perform dimension reduction. Benjamini and Hochberg false 379 discovery rate correction factor (55) errors in null hypothesis testing when conducting 380 multiple comparisons.

381 **Results**

382 Demographic and clinical characteristics

383 Demographic and clinical characteristics at the beginning of the study were similar in

- both randomized groups. A total of 60 individuals were included for this investigation,
- 385 30 per group, but 3 patients abandoned voluntarily the investigation after visit 1 for
- 386 personal or work-related circumstances. All of them were in the Control Group.
- 387 Ultimately, the study was comprised of 57 patients, 30 in the Study Group (Sugar Shift
- 388 Group) and 27 in the Control Group (Control Group).

Among the patients studied, there was a preponderance of the female sex for both groups (Sugar Shift Group 60.0%, Control Group 51.9%). On average, the patients were approximately 55 years old, minimum age 33 and maximum 65. No significant differences were found in terms of sex (p = 0.725) or age (p = 0.120).

The distribution of patients according to nutritional assessment showed overweight and obesity (Sugar Shift Group 53.3% and Control Group 51.9%). Patients were less commonly of normal weight. No significant differences (p = 0.722) were detected in both groups.

Regarding the type of treatment, diet plus oral hypoglycemic agents prevailed in both cohorts (Sugar Shift Group: 63.3%, Control Group: 55.6%). No significant differences were found regarding the type of treatment between the two groups (p = 0.549).

400 Safety of the Symbiotic Product

401 No adverse events were reported by participants in the Sugar Shift group. One

402 participant in the Control Group complained of bloating during the second visit (day403 28).

404 Creatinine levels were measured and monitored to assess the impact, if any, Sugar

405 Shift has on kidney function (56). Normal levels of serum creatinine are 65.4 µmol/L to

406 119.3 μ mol/L (57).Mean creatinine levels were not significantly different (p = 0.24)

407 between the Control Group at day 1 (77.17 µmol/L) and the Sugar Shift Group at day 1

408 (77.98 μ mol/L). Similarly, there were no significant differences (p = 0.21) between the

409 control and the study group at the conclusion of the study with values of 77.17 µmol/L

410 in the control group and 77.97 µmol/L in the group receiving Sugar Shift.

411 Clinical Chemistry

412 Fasting Glucose (FBG)

413 Fasting glucose levels showed that in three months this parameter is stabilized in the

- 414 Sugar Shift Group as compared with the Control Group See Fig 3.
- 415

Fig 3. Variance trends in the Control Group and Sugar Shift Group cohorts during the 84day study period.

- 418 Variances for each sample set was calculated and plotted at four sample periods
- 419 *indicated in Fig 2. Trend lines for each cohort are represented by dashed line. Solid*
- 420 *lines represent the plot of the actual variances. Red-colored lines represent results for*
- 421 the Control group and Purple-colored lines represent the variances of the Sugar Shift
- 422 group. (a) Variance trends for fasting glucose. (b) Variance trends for 2-hour
- 423 postprandial glucose

424

- In the Sugar Shift Group, the median FBG was 7.5 mmol/L (135 mg/dL) at the
- 426 beginning of the study and remained at 7.2 mmol/L at the second (day 28) and third
- 427 doses (day 56) and resulted in an FBG value of 7.2 mmol/L (129.6 mg/dL) at the end of
- 428 treatment, with no significant differences between different times (p = 0.942). In the
- 429 Control Group, the behavior was different. There was a significant (p = 0.001) increase
- 430 in the median FBG value between the first and last day of treatment (7.5 mmol/L vs. 8.0
- 431 mmol/L) (Table 2).
- 432

Table 2. Levels of T2DM biomarkers	during the course	of the study.
------------------------------------	-------------------	---------------

		Study Days				
Variables	Cohort	Day 1	Day28	Day 56	Day 84	r voluo
		Descriptive s	statistics: M	edian (IR)*		value
Fasting	SS** Group	7.5† (4.5)	7.7 (5)	7.4 (5.1)	7.2 (4.1)	0.942 ª
(mmol/L)	C** Group	7.5 (3.9)	7.3 (4.3)	7.8 (4.1)	8.0 (2.6)	0.001 ^a
2h Post-	Sugar Shift Group	11.1 (7.3)	11.5 (5.9)	10.1 (8.4)	10.9 (8.2)	0.646 ª
(mmol/L)	C Group	9.5 (5.8)	10.1 (6.1)	9.3 (6.3)	10.8 (6.3)	0.013 ª
HbA1C	SS Group	7.2 (1.9)	ND	ND	7.2 (1.9)	0.262 ^b
(%)	C Group	6.8 (2.1)	ND	ND	7.2 (3.4)	0.387 ^b
HOMA IR	SS Group	8.65 (5.5)	ND	ND	7.12 (3.9)	0.002
index	C Group	11.54 (14.2)	ND	ND	12.51 (8.2)	0.191

434

435 * *IR = Interquartile Range*

436 ***SS = Sugar Shift treated cohort; *C = Placebo control cohort*

437 *a= Friedman Test*

438 † Multiply the value in mmol/L by 18 to obtain values in mg/dL

439

440 In consideration of the differences observed at the end of treatment between both

- 441 groups (day 56 and Day 84), we performed the analysis of variance between both
- 442 groups. The variability of FBG in Control Group is much greater (23.88) than in Sugar
- 443 Shift Group (8.26) after 12 weeks of treatment (84 days) (Table 3, Fig 3a). The Analysis
- 444 of Covariance (ANCOVA) (48) was in concordance between both groups at 84 days.
- 445 The ANCOVA results show a negative covariance between groups (z=-6.85, p(z)=
- 446 7.62257E-12), indicating that fasting glucose increases in the Control group and
- 447 decreases in Sugar Shift Group at the end of 12 weeks (Table 3).

448	Table 3: Comparison	of variances	between groups	in fasting glucose	levels
			<u> </u>		

		Study Days					
Variable	Day 1	Day28	Day 56	Day 84			
		Des	criptive stat	istics: Varianc	ce (Mean)		
Fasting Glucose	Sugar Shift Group	7.30(8.29)	7.31 (8.29)	11.49 (8.48)	8.99(8.31)		
(mmoi/L)	C. Group	8.59(8.43)	8.59(8.43)	19.34(8.34)	23.9 (9.4)		
P(F<=f) one-tail	0.33	0.33	0.089	0.006			
P(Z<=z) one-tail		0			3.81128E-12		
P(Z<=z) two-tail		0			7.62257E-12		
F Critical one-tail	1.891466319						
z Critical one-tail	1.644853627						
z Critical two-tail	1.959963985						

449

450 *Postprandial glucose – 2h*

451 Regarding postprandial glucose, the median values in Sugar Shift Group were 11.1 and 452 11.5 mmol/L in the early stages of the study and in the last two measurements, showed 453 a slight decrease (10.1 and 10.9 mmol/L) that was not significant (p = 0.646). In the 454 Control Group, however, a slight increase at the end of the treatment was significant with 455 respect to the stable values of the Sugar Shift group (p = 0.013) (Table 2). The declining 456 trend in pp glucose from day 1 to day 84 was similar to FBG (Fig 3b) even when no 457 significant differences was observed at the end of the study in analysis of variance between both groups (p = 0.62). The ANCOVA results show a negative covariance 458 459 between the Control group (26.817)and the Sugar Shift group 460 (-0.0289), indicating that postprandial glucose increases in the Control group and 461 decreases in Sugar Shift Group at the end of 12 weeks. The kinetics of cohort variances 462 throughout the study for both FBG and PPG can be observed in Fig 3.

463 *Glycosylated Hemoglobin (HbA1C)*

The analysis of HbA1C showed that no significant change occurred in either the Sugar Shift Group or the Control Group. Glycosylated hemoglobin was found, on average, at 7.2% in the two measurements made (day 1 and day 84) in the study group. In patients in the Control Group, at baseline, it was 7.3% and, at the end, 7.4%. No significant differences were found (Table 2). It is noteworthy that a 90-day trial period may not have been sufficient for either group to be a clear indicator of improvement in view that the RBC cycle is approximately 120 days (58).

471 *Cholesterol*

472 The data collected during this aspect of the study, as well as the metadata of the X participating patients, are listed in Table S1 TABLE S1. Mean cholesterol levels were not 473 474 significantly different (p =0.371) in the Sugar Shift Group while there was a significant 475 (p = 0.0007) increase in mean cholesterol values in the Control Group. The F-test Two-476 Sample for Variance analysis revealed a significant increase (p = 0.00032) in variance 477 from day 1 to day 84 for the Control Group but not significant (p = 0.391) for the Sugar 478 Shift Group. Mean cholesterol values for the Control Group were 4.41 mmol/L at day 1 479 and 5.14 mmol/L at day 84. For the Sugar Shift Group, mean cholesterol values 480 remained steady at 4.31 mmol/L at day 1 and 4.42 mmol/L at day 84. Variances for this 481 latter group were 0.645 and 0.584, respectively. For the Control Group at days 1 and 482 84, the variances were 0.311 and 1.644, respectively.

483 HDL and LDL Cholesterol

484 The means of the HDLc values of day 1 and day 84 for the Sugar Shift group were 1.19

- 485 and 1.39, respectably. Similarly, the mean values for the Control group were 1.17 and
- 486 1.12 for Days 1 and 84, respectively. These values were not statistically significant
- 487 when the two groups were compared. The variances, however, between Day 1 and 84
- 488 of the SS group were 0.12 and 2.72, respectively. These were statistically significant (p
- 489 = 0.00012). The Control group, however showed no significant (p = 0.137) variances
- 490 between Day 1 (variance = 0.07) and Day 84 (variance = 0.11).

491 *Triglycerides*

- 492 Triglyceride levels were reduced, on average, from 2.1 to 1.7 mmol/L in the Sugar Shift
- 493 Group and from 2.4 to 1.6 mmol/L in the Control Group, results that were significant in
- 494 both cases (Sugar Shift Group: p = 0.005; Control Group: p = 0.002). The analysis of
- 495 variance between groups no showed significant differences.

496 *Insulin*

- 497 Insulin levels were measured for all study participants and then analyzed statistically
- 498 using both the t-Test (paired) and F test for analysis of variance. The Control Group
- 499 (Days 1 and 84) and Sugar Shift Group (Day 1) participants showed higher insulin
- 500 concentrations than those in the Sugar Shift Group after 84 days of treatment (Table 4).
- 501 Using the t-Test Paired Two-Sample for Means the p values for Sugar Shift Group Day
- 502 1 and Sugar Shift Group Day 84 was p = 0.02 and interpreted as significant.
- 503 Conversely, the Control group (Day 1 and Day 84), and Control Day 1 and Sugar Shift

Group Day 1 were 0.12 and 0. 11, respectively. However, the p value. For this latter
pair, the Mean for Day 1 participants was 9.01 with a Variance of 92.24 as compared to
the Sugar Shift Group Day 84 group, which showed a Mean of 7.09 and a Variance of
29.05. By way of comparison, the Mean values for Control Group Day 1 and Control
Group Day 84 were 11.27 and 12.34, respectively with corresponding Variances of
131.44 and 170.74.

- 510 The F-test showed similar results. Day 1 of both groups were not significantly different
- 511 (p = 0.192) while for Day 84, the Control and Sugar Shift participants were significantly
- 512 different (p = 2.41 x 10⁻⁶) with means of 12.5 μ U/L for the Control Group and 8.64 μ U/L
- 513 for the Sugar-Shift treated group, representing a 30.9% reduction in insulin levels in
- 514 those patients receiving the symbiotic formulation.

515 Table 4. Statistical analysis using the t-Test for Paired Samples for Means for serum insulin in the treated and control

516 **groups**

	t-Test: Paired Two Sample for Means - Insulin (mIU/L)									
	SS_D1*	SS_D84	C_D1*	C_D84	CD_D1*	SS_D1	C_D1*	SS_D84		
Mean	9.00694744	7.08535518	11.2669246	12.334936	11.2669246	7.86968928	12.334936	6.2201627		
Variance	92.241692	29.057633	131.74252	172.73747	131.742529	37.454623	172.737474	15.9212268		
Observations	31		27		27		27			
Pearson Correlation (59)	0.9131	98142	0.9362	99149	-0.126860439		-0.047453887			
df	30 26		6	26		26				
t Stat	2.0688	372866	-1.1833	98856	1.2908	314199	2.283333364			
P(T<=t) one-tail	0.023634798		0.123679404		0.104064286		0.015413179			
t Critical one-tail	1.697260887		1.70561792		1.70561792		1.70561792			
P(T<=t) two-tail	0.0472	0.047269596		0.247358807		0.208128571		0.030826357		
t Critical two-tail	2.0422	2.042272456		2.055529439		2.055529439		2.055529439		

517 **SS = Sugar Shift Cohort, C = Control Cohort, D1 = Day 1 of the study; D84 = Day 84 of the Study.*

518 Insulin Resistance

- 519 HOMA-IR, as an indicator of insulin resistance, was calculated according to the
- 520 formula: fasting insulin (μU/L) x fasting glucose (nmol/L)/22.5. The Control Group
- 521 (Days 1 and 84) and Sugar Shift Group (Day 1) participants showed higher HOMA-IR
- 522 values than those in the Sugar Shift Group after 84 days of treatment (Fig 4).
- 523 Boxplots were generated using the script "ggboxplot" in the library "ggppubr"
- 524 (https://cran.r-project.org/web/packages/ggpubr/index.html) with "jitter" to show
- 525 data distribution.
- 526

527 Fig 4. Boxplots showing distribution data gathered from HOMA-IR calculations of

528 before and after treatment for both the Control Group- and Sugar Shift Group-

- 529 treated cohorts.
- 530 *Boxplots were plotted with <u>ggboxplot</u> using pairwise comparisons among the four*
- 531 *possible groups. The "jitter" function was added to show the distribution of*
- 532 datapoints for each of the pairwise comparisons and to assess the relationship
- 533 between the measurement variable and the categorical variable. The significance (p
- 534 = 0.05) in Chao1 indices between each group pair is illustrated as the probability
- 535 value as calculated using the Wilcoxon signed-rank test (values on top of each
- 536 *graph*)

537

538 Using the F-Test Two-Sample for Variance, the p values between the Control Group 539 (Day 1 and Day 84) and Control Group Day 1 and Sugar Shift Group Day 1 were 0.24 540 and 0.18, respectively. However, the p value for Sugar Shift Group Day 1 and Sugar 541 Shift Group Day 84 was p = 0.0071 and interpreted as significant. For this latter pair, 542 the Mean HOMA-IR index was 11.27 with a Variance of 94.19 as compared to the 543 Sugar Shift Group Day 84 group, which showed a Mean of 8.84 and a Variance of 544 28.13. By way of comparison, the Mean values for Control Group Day 1 and Control 545 Day 84 were 11.27 and 12.33, respectively with corresponding Variances of 131.74 546 and 172.74.

547 Serum Lipopolysaccharides (LPS)

Serum LPS was measured for all participants in the two cohort groups. The results are summarized in Fig 5 and Table 5. There was a significant difference between day 1 and day 84 in the Sugar Shift Group (0.00099). Similarly, significant differences were observed in the levels of serum LPS between the Control and Treated groups after 84 days of treatment (p = 0.012). No significant difference was noted in the Control Group (p = 0.0.922).

554

555 Fig 5. Violin plots showing the distribution of LPS values for each study group.

556 Violin plots were chosen to show the distribution of LPS values of samples within

557 each study group. Wider sections of the violin plot represent a higher probability that

558 *members of the population will take on the given value; the skinnier sections*

- 559 represent a lower probability. The colored dots within the bar plot represent the
- 560 *mean values for the study group while the black line indicates the median.*
- 561 Table 5. Paired samples t- Test for means among cohorts and sample times for serum
- 562 LPS

Pair	Mean Diff	Variance Diff	Pearson Correlation	t statistic	p value	Significance*
CD01- CD84	0.038875	0.007078	0.91995	1.77522	0.92199	NS
SSD01- SSD84	0.150666	0.816646	0.29366	4.02503	0.00099	S
SSD01- CD01	-0.00537	-0.01091	-0.18955	-0.0727	0.47202	NS
SSD84- CD84	-0.12833	-0.02032	-0.35052	-2.5965	0.012	S

563 *NS = not significant; S = significant

564 Microbiome analysis

- 565 A total of 40 samples, 10 samples from each cohort were collected before and after
- treatment and processed as described above. The mean sequence length per
- sample was $21,333 \pm 7,288$ base pairs (bp) with a mean Q value of 37.2 as
- 568 determined using FastQC (60).

569 Alpha Diversity

- 570 Species richness, as determined using the Chao1 Index (50), showed a significant
- 571 increase (Wilcoxon's signed-rank test) (61) between Day 1 of treatment with Sugar
- 572 Shift and day 84 (p = 0.0089). Similarly, there was a significant difference between
- 573 the Control and the Treatment group at the end of the 12-week study (p = 0.011). No
- 574 such significant differences were noted between the two groups at the beginning of

575	the study ($p = 0.80$) or the Control Group at the beginning and end of the study ($p =$
576	0.80). No significant difference in the Shannon Diversity Index as measured by the
577	Wilcoxon's rank test was observed among the various groups. Good's Coverage (51)
578	of data showed no significant difference in coverage among the two groups, before
579	and after treatment. The mean coverage was 99.83 \pm 0.54. Alpha Diversity (Chao1)
580	boxplots with "jitter" are shown in Fig 6.

581

582 Fig 6. The Chao1 alpha diversity of Control Group- and Sugar Shift Group-treated

583 patients is represented in boxplots with jitter showing inter- and intra-group data

- 584 distribution.
- 585 *The number of species in each of the pairwise comparisons of fecal microbiomes*

586 *are illustrated in these graphs as the Chao1 Index. Each dot represents a data point*

- 587 for each sample. The significance (p = 0.05) in Chao1 indices between each group
- 588 pair is illustrated as the probability value as calculated using the Wilcoxon signed-
- 589 rank test (values on top of each graph).
- 590

591 Beta Diversity

- 592 No significant changes were noted in Beta Diversity among the groups evaluated.
- 593 UPGMA clustering(62) revealed that microbiome samples from individuals clustered
- together, regardless of the date of sample collection. While the results show a
- 595 difference in Unifrac distances (37) between Day 1 and Day 84 in the Sugar Shift
- 596 cohort, this difference was not statistically significant (p = 0.989).

597 Taxonomic Biomarkers

598 Taxonomic biomarkers were determined using both Kruskal-Wallis H test (39) and 599 LefSe analysis (40). Two taxonomic biomarkers were identified. When comparing 600 Day 1 and Day 84 of the Sugar Shift treated cohort, several taxonomic biomarkers 601 were identified, both, via the Kruskal-Wallis H test and LEfSe analysis. Significant 602 increases in abundance of several genera of the *Lachnospiraceae* family (p = 0.008), 603 specifically *Blautia* (p = 0.02008), *Dorea* (p = 0.02448), *Coprococcus* (p = 0.0322) 604 and *Kineothrix* (p = 0.2378) as well as *Prevotella* (p = 0.013) and *Bifidobacterium* (p = 605 0.011) and *Faecalibacterium prausnitzii* (p = 0.0018. Significant decreases in relative 606 abundance of *Enterococcus* (p = 0.04696), *Vagococcus* (p = 0.00335), 607 *Ruminococcus* (p = 0.04116) and *Peptostreptococcaceae* (p = 0.04508). *Clostridium innocuum* group, showing a decrease from 0.05211 on Day 1 of the 608 609 study to 0.00183 at Day 84 with an LDA effect size of 3.10536 and a p-value of 610 0.03051. Conversely an increase in Agathobaculum sp. was noted from day 1 611 (0.16824) to Day 84 (0.44657) with an LDA effect size of 2.34567 and a p-value of 612 0.4254.

613 Functional Biomarkers

- 614 Profiling phylogenetic marker genes, such as the 16S rRNA gene, is a key tool for
- 615 studies of microbial communities but does not provide direct evidence of a
- 616 community's functional capabilities. PICRuSt was developed for predictive
- 617 functional capabilities using 16S rRNA. Functional prediction using PICRUSt (63, 64)
- and LEfSe (41) revealed significant differences between the Day 1 and Day 84 of

- 619 treatment with Sugar Shift in the gut microbiome in the relative abundance of
- 620 microbial genes related to certain metabolic pathways associated with carbohydrate
- and lipid metabolism (Table 6).
- 622 Table 6. Principal Functional Biomarkers identified by PiCRUSt and LEfSe Analysis
- 623 of Treated in the Sugar Shift cohort.

		Relative Abundance of Genes			
Ortholog	Definition	p-value	SugarShift Day 1	SugarShift Day 84	% Diff
K09884	Aquaporin related protein, invertebrate	0.006302132	9.24575E-05	3.4468E-06	-96%
K13319	4-ketoreductase	0.016411893	8.132E-07	5.5744E-06	585%
K16913	proline-, glutamic acid- and leucine- rich protein 1	0.028365506	8.39499E-05	0.0001535 3	83%
K07224	iron uptake system component EfeO	0.028365506	0.001658944	0.0028216 4	70%
K15578	nitrate/nitrite transport system ATP-binding protein	0.034293721	0.015285072	0.0115972 9	-24%
K21113	cytochrome P450 family 106	0.035999193	3.214E-07	3.2456E-06	910%
K22317	acyl-CoA:acyl-CoA alkyltransferase	0.035999193	6.427E-07	4.9079E-06	664%
K22336	bacterioferritin B	0.035999193	6.427E-07	4.6237E-06	619%
K00691	maltose phosphorylase	0.049366195	0.002707086	0.0007913 5	-71%

624

625 Discussion

- 626 In this study, we have shown that in a short period of administration (twice daily for
- 627 12 weeks) of the symbiotic formulation Sugar Shift to T2DM patients, there were
- 628 significant differences between the treated and control group on several key metrics:

fasting blood glucose, insulin, HOMA-IR and serum LPS. This study also provides
evidence that supports the benefits of the administration of this formulation as an
adjunct therapy for the control of insulin resistance and in the lipidic profile in
diabetic. The HbA1C and postprandial glucose, however, did not show significant
differences as compared to placebo.

634 Meta-analysis studies have been summarized for a great diversity of published

635 studies in which different probiotic formulations have been evaluated for patients

suffering from T2DM (65, 66). Many of these studies have shown significant

variations in the values of HbA1c and fasting glucose. (67-69). Others, however, have

638 not shown such movements. (70, 71).

639 Measuring HbA1c is an accepted and valued method to estimate long-term average

640 glycemia (72). These levels are associated with erythrocyte (RBC) longevity in

641 peripheral circulation. Erythrocyte survival curves turnover may explain the

642 discrepancy in the reported results (67-69, 71). The strong correlation of glycation

rate with whole blood HbA1c in the DM and NDM subjects provides evidence that

the whole blood determination depends on the integration of glycation rate

645 throughout the red cell life span (73). In addition to RBC life span, there may be other

646 variables that either attenuate or amplify the discordances between Hb A1c and

average plasma glucose. In healthy adults, complete turnover average 120 days,

648 during which time approximately 1.7 x 10¹¹ cells are renewed each day (74). The

analysis conducted on RBC survival curves from Cohen et al. (73) suggests an

average erythrocyte circulation time of 80 \pm 11 days. In view of this observation, it

35

651 can be assumed that a large proportion of the glycosylated erythrocytes present in 652 peripheral circulation of both the study cohorts at the beginning of the study were 653 still present after 84 days. These observations may explain the similarity in the levels 654 of HbA1c at both sampling times. A 3-month study is not sufficiently long to clearly 655 assess the effect of the test substance (Sugar Shift) on HbA1c levels. Therefore, it is 656 recommended that future studies may be extended for an additional 3 months to 657 assess the impact of Sugar Shift, if any, on HbA1c levels.

658 Clinical Chemistry

To analyze the effects of Sugar Shift on glycemic control evaluated by FBG,

660 postprandial glucose and HbA1c levels, it is important to analyze the characteristics

of the patients who participated in the study. As can be seen from the median

values, both groups consisted of individuals with stable values of their glucose and

663 HbA1c parameters due to previously implemented diabetic treatments. This reflects

the action of the hypoglycemic treatments that most of both cohorts were taking

665 prior to the beginning of the study as well as the intervention of the endocrinologists

in their follow-up during the time of the COVID 19 pandemic, which preceded the

667 study (75-77).

668 Serum glucose and HbA1c

At the latter part of the study period (days 56 and 84) it was observed that the FBG

values of the individuals in the control group increased significantly (Fig 2). Glucose

671 levels in the Sugar Shift Group, on the other hand, remain constant, with a tendency

to decrease towards the final day of the study (day 84). These data differ significantly
between study groups. F-test data showed a p = 0.006 when comparing the

674 variance between the Control and the Sugar Shift Group at the end of the study.

675 Covariance studies (78) showed a negative covariance (-0.6086977), that is, they are

676 moving in opposite directions (78). These results indicate that while levels of FBG are

677 increasing the Control Group, they are decreasing in the Sugar Shift Group, and for

the 84-day study, these values remained stable in the Sugar Shift cohort.

The meta-analysis by Hu Y-m, et al. (66) on the effects of different probiotic

680 supplements in patients with T2DM showed that, in many studies the probiotic

681 supplements evaluated, regardless of the study design, the duration of treatment (6-

682 12 weeks) and the doses of the supplements produce a slight reduction in FBG and

an inappreciable change in HbA1c. These results are in concordance with the results

684 presented here.

Among the possible mechanisms of probiotic therapy is promotion of a

686 nonimmunologic gut defense barrier, normalization of increased intestinal

687 permeability and improved gut microecology play key roles. Another possible

688 mechanism of probiotic therapy is improvement of the intestine's immunologic

barrier, particularly through intestinal immunoglobulin A responses and alleviation of

690 intestinal inflammatory responses, which produce a gut-stabilizing effect (79, 80).

Our results also suggest that if stabilization occurs after day 56, this trend should be

692 evaluated over a period longer than 3 months. Studies evaluating the action of

693 probiotics in longer periods of time find significant decrease in HBA1c and FBG

694 values (65, 81, 82).

695 Another important aspect in the optimal T2DM management is the PP Glucose 696 control. This parameter is often difficult to achieve because different mechanisms 697 are involved. The macronutrients composition and also the sequence and timing of a 698 meal gastric emptying/intestinal glucose absorption, gastrointestinal hormones, 699 hyperglycemia mass action effects, insulin/glucagon secretion/action, de novo 700 lipogenesis and glucose disposal are integrated via the central nervous system for 701 optimal regulation and potentially, to reduce postprandial glucose fluctuations and 702 thereby, HbA1c (83, 84). The contribution of the microbiome to this control, 703 particularly in post prandial glucose is not well recognize yet, but our results showed 704 a coincident tendency in the behavior of FBG and Post Prandial Glucose, so we 705 believe that the symbiotic intervention in a period more than 12 weeks is a promising 706 approach to regulate via gut healthy bacterial the hyperglycemia after meals in 707 T2DM patients (85).

708 Considering the above, as well as the results obtained, we can hypothesize that 709 Sugar Shift promotes a stabilization of the gut microbiome as a precursor to a 710 noticeable decrease in FBG. This process could be due to the impact of Sugar Shift 711 on the relative abundance and composition of the gut microbiota during the course 712 of treatment. Sugar Shift was designed to endogenously convert glucose and 713 fructose to mannitol in the GI tract The principal producers of mannitol in the 714 consortium are Leuconostoc mesenteroides and Lactobacillus reuteri (results not 715 shown here), and the principal glucose consumer are *B. longum* and *B. bifidum* (82). 716 In addition, the symbiotic formulation controls the inflammation by butyrate

717 production as indicated by an increase in the number of genes and species

associated with butyrate production in the study group at Day 84. *Pediococcus*

719 acidilactici, Lactobacillus paracasei, Bifidobacterium longum and Lactobacillus

reuteri are the principal butyrate producers in the Sugar Shift consortium. The net

production of butyrate was predicted by the BioFlux[™] model to be 4.5 x 10⁵ mmol/h

- (86). Thus, the Sugar Shift therapy may help stabilize the gut microbial environment
- in 12 weeks of treatment and thereby prevent the generation of inflammatory

mediators such a LPS and T2DM dysregulation (16, 80, 87).

725 *Lipids*

726 The analysis of the lipid profile shows a stabilization in the normal values of 727 cholesterol in the Sugar Shift Group and a significant increase of these values in 728 Control Group. Longer term studies are needed to assess the full impact on blood 729 cholesterol. The colonization of the intestine by *Bifidobacterium* and *Lactobacillus* 730 probiotics may affect the regulatory mechanism of conversion of cholesterol into bile 731 acids and its elimination in the feces (88). These probiotic bacteria likely incorporate 732 the cholesterol into their plasma membrane, convert it into coprostanol and 733 deconjugated bile acids by the activity of the enzyme bile salt hydrolase (BSH) (89, 734 90). The activity of the BSH increase with the long-term colonization of the gut by 735 Bifidobacterium- and Lactobacillus-containing probiotics, promoting a higher degree 736 of BSH activity, thus, increasing the production of deconjugated bile acid (88). The 737 decrease in cholesterol by this metabolic pathway would explain the slight increase

in HDLc in the Sugar Shift Group, since the elimination of excess cholesterol wouldnot be through the main pathway.

740 The decrease in triglyceride levels was significant in both groups. In the treated aroup it could be due in part to the regulation exerted by probiotic bacteria (91) 741 742 linked to the diet (92) and increased physical activity of individuals in both study 743 groups (93). The analysis of physical activity, as measured by questionnaire, showed 744 that physical activity was higher in the Control Group compared to Sugar Shift 745 Group (66.6% vs 50%, respectively). This suggest that the effect of the probiotics 746 regulatory mechanism could be increase by the incorporation of physical exercise. 747 Animal studies indicate that the composition of gut microbiota may be involved in 748 the progression of insulin resistance to type 2 diabetes (94). Several meta-analysis 749 studies on the use of probiotics in T2DM show that most of these nutritional 750 supplements decrease insulin in a short period of time significantly, even if other 751 parameters such as HbA1c are not modified (65, 66, 91, 95). This is consistent with 752 what was found in our study.

753 *Insulin*

Insulin resistance is a pathological state in which tissues do not respond normally to
insulin in the process of glucose metabolism (96). Various factors have been
implicated in the pathogenesis of insulin resistance (23, 97-99), including genetic
predisposition, aging, obesity, and a sedentary lifestyle. More recently, the gut
microbiota has been considered to be a key factor leading to the insulin resistance
(100). The exact microbial mediators and mechanisms that link features of different

760 gut microbial communities to changes in insulin secretion are not yet known (101). It 761 is possible that microbes or their components such as muropeptides and LPS, 762 penetrate the gut barrier and interact with receptors within the pancreas or insulin-763 responsive tissues and compromise endocrine control of metabolism and promote 764 hepatic and peripheral insulin resistance, thereby worsening blood glucose. The 765 LPSs interaction with Toll-like receptor 4 promotes inflammation in metabolic tissue 766 and this innate immune response could be involve in the poor control of blood 767 glucose. So, probiotics may be a promising approach to improve insulin sensitivity 768 by favorably modifying the composition of the gut microbial community by the 769 modification of the gut bacterial and reducing intestinal endotoxin concentrations. 770 thus reducing inflammatory signaling and decreasing the insulin resistance (101).

771 Microbiome Analysis

Species richness showed a significant increase (Wilcoxon's rank-sum test) between Day 1 of treatment with Sugar Shift and day 84 (p = 0.0089). This suggests that the microbial consortium promotes an increased diversity in the gut microbiome. higher microbiome a diversity, along with more butyrate-producing gut bacteria, was associated with less T2DM and with lower insulin resistance among individuals without diabetes (102, 103).

778 Our study indicates that the use of symbiotic formulation Sugar Shift induces a

- significant modification of LPS concentration that is in concordance with the
- 780 modification of insulin resistance, lipids modification and FBG reduction. The
- 781 microbiome analysis confirms this hypothesis. The gut microbiome dysbiosis of

782 patients with T2DM correlates well with increased LPS levels and its impact on the

783 presence of inflammatory biomarkers in serum, which may provide insight into

784 potential diagnostic and therapeutic approaches in the treatment of T2DM (104).

785 Taxonomic biomarkers

786 Gut microbiota-derived LPS is an important factor involved in the onset and

787 progression of inflammation and metabolic diseases, including T2DM (105). The

composition of the gut microbiota is altered in T2DM with a concomitant reduction

of SCFA producers, notably butyrate (106). LPS, bacterial surface glycolipids,

790 produced by Gram-negative bacteria are known to induce acute inflammatory

reactions (107), particularly in the context of sepsis. However, LPS can also trigger

chronic inflammation (104). In the case of T2DM and other metabolic diseases

originating from chronic inflammation of the gut, the source of LPS is not an external

infection, but rather an increase in endogenous production, which is usually

sustained by the gut microbiota (107).

The microbiome analysis showed a significant increase (p > 0.01) in abundance of

several genera of the Lachnospiraceae family in treated group as compared to

control group. The compiled data from the Human Microbiome Project (108, 109)

and Meta Hit (110) revealed that the human microbiota comprises 12 different phyla,

of which 93.5% belong to Firmicutes, Bacteroidetes, Proteobacteria, and

801 Actinobacteria. Among these, Firmicutes and Bacteroidetes dominate the gut

802 microbiota in healthy subjects. The Lachnospiraceae family is a phylogenetically and

803 morphologically heterogeneous taxon belonging to the clostridial cluster XIVa of the

804 phylum Firmicutes (37). Lachnospiraceae belong to the core of gut microbiota,

805 colonizing the intestinal lumen from birth and increasing, in terms of species

richness and their relative abundances during the host's life. However although,

807 members of Lachnospiraceae are among the main producers of SCFA, different taxa

808 of Lachnospiraceae are also associated with different intra- and extraintestinal

diseases, that is why this genera of bacteria have a controversial role in health and

810 disease (111). This association depends on the predominant species of this genera

811 in the microbiome (111, 112).

812 In a normal human physiologic state, 90–95% of the SCFAs present in the colon and 813 in the general systemic circulation are constituted by acetate, propionate and 814 butyrate, with intraluminal concentrations of approximately 60% C2, 25% C3 and 815 15% C4 (113). Butyrate is a SCFA reported to be the major source of nutrition for 816 colonic epithelial cells (114) with anti-inflammatory effects by induction of regulatory 817 T cells, downregulation of pro-inflammatory cytokines and the Toll-like receptor 818 (TLR) 4 receptors, thus reinforcing insulin sensitivity and glucose metabolism.(115). 819 On the other hand, butyrate induces the Activation of G protein-coupled receptor 820 (GPR) 43. This binding suppresses colonic inflammation, therefore protecting the 821 liver and down- regulating insulin signal transduction in adipose tissue. Butyrate is 822 also involved in modulating appetite and lipolysis inhibition, which in turn, decrease 823 circulating lipid plasma levels and body weight (113). Recent studies on the 824 composition and functionality of the microbiome in obese children demonstrated 825 that insulin resistance was associated with decreased microbial a-diversity

826 measures and abundance of genes related to the corresponding metabolic827 pathways (116).

In our results we found a significant increase of α diversity at Day 84 in the group of treatment with Sugar Shift. These data support our hypothesis because of the significant decrease in LPS concentration and in HOMA-IR Index in the treated group with Sugar Shift are related to de increase of α diversity in the microbiome of this people.

833 There was a significant (p = 0.025) increase in the relative abundance of

834 *Bifidobacterium* spp. between both pre-treatment groups (0.63 \pm 1.14) and the

Sugar Shift Group after 12 weeks of treatment (2.75 \pm 3.84). Increased relative

abundances of this genus is notably reported in association with successful

treatment with probiotics and in non-diabetic, "healthy" individuals (117, 118). It is

also plausible to hypothesize that the Bifidobacteria present in Sugar Shift colonize

the intestines and help restore the homeostasis of the gut microbiota and increase

840 the relative abundance of SCFA producers, thus, alleviating inflammation. This

interaction, however, would need to be supported by whole genome and

842 metabolomic studies.

843 It is noteworthy that *Faecalibacterium prausnitzii* is a highly represented (44%

increase from the same patients at the beginning of the study) in the gut microbe of

845 Sugar Shift-treated patients. This taxon is generally abundant in the microbiome of

846 "healthy" individuals, but it is present at reduced levels in individuals with

gastrointestinal inflammatory diseases (e.g., diabetes). It has therefore been

suggested to constitute a marker of a healthy gut and is associated with anti-

849 inflammatory properties (119, 120). Among its attributes, *F. prausnitzii*, is an acetate

850 consumer that produces butyrate and bioactive anti-inflammatory molecules such as

851 shikimic and salicylic acids (121). This protective system SCFAs that are significant

852 end-products that re involved in the fermentation process of the bacteria that exist in

the human colon and ameliorates the effects of LPS (122). The significant decrease

in serum LPS noted among the Sugar Shift-treated study group (Fig 3) may be

attributed, at least in part, to the role of *F. prausnitzii* in the production of SSFAs and

856 other anti-inflammatory substances.

857 Functional biomarkers

858 Putative, functional biomarkers were identified using PICRUSt2 to infer functional

gene relative abundances from taxonomic data and LEfSe to determine

860 discriminatory features that explain functional and taxonomic between the study

groups. While these tools serve to identify differences based on gene relative

abundance, rather than by function, it is noteworthy that several of the

863 discriminatory orthologs identified play a role in T2DM. Many of which are related to

iron metabolism, in particular orthologs K07224, K22317, and K22336.

865 The blood sugar levels are closely related to the iron contents in islet b-cells.

866 However, because of the higher expression levels of iron transport proteins in the

islet b-cells when compared with other tissue cells, the islet b-cells are more likely to

868 accumulate iron. Excessive levels of iron might induce excessive oxidative stress

869 promote islet b-cell apoptosis, and ultimately affect insulin secretion and increase

870 the risk of insulin resistance (123, 124). Circulating levels of key soluble proteins for 871 body iron homeostasis are altered in individuals with obesity, insulin resistance 872 and/or type 2 diabetes mellitus (125). It appears that the intestinal iron availability 873 affects the gut microbiome, which in turns plays a central role in the absorption of 874 iron in the intestine and bacteria-derived metabolites. This two-way interaction 875 between iron homeostasis and the gut microbiota affects systemic glucose 876 metabolism (126). The observation that important iron-processing orthologs are 877 significantly overexpressed in the Sugar Shift-treated group seems to suggest that 878 this formulation alleviates insulin resistance by promoting iron homeostasis via 879 promotion of a "healthier" microbiome. 880 The high relative abundance of ortholog gene K22317 (acyl-CoA:acyl-CoA alkyl

transferase) in Sugar Shift-treated individuals is noteworthy as this gene is involved
in the regulation of lipid metabolism and subsequent lipid transformation.(127). This
process was discussed above in relation to cholesterol levels in Sugar Shift-treated
individuals.

885 Conclusions

886 Sugar Shift is a symbiotic formulation consisting of a sustainable bacterial guild that

promotes the conversion of glucose and fructose to mannitol and promotes the

- 888 production SSFAs acetate and butyrate. The results indicated that consumption of
- 889 Sugar Shift twice daily for 12 weeks, in conjunction with standard of medical care for
- T2DM (72) improves biomarkers for T2DM, including, HOMA-IR index and serum
- 891 Insulin and LPS levels.

892	1.	Fasting glucose and HbA1c levels were stabilized during the course of the
893		study, showing a progressive improvement over the course of the study.
894	2.	In this study it was shown that supplemental treatment of T2DM with Sugar
895		Shift increases alpha diversity of the gut microbiome, which has been
896		associated with a reduction of the biomarkers of T2DM (128, 129).
897	3.	Insulin resistance was significantly improved in patients treated with Sugar
898		Shift as compared to the Placebo group. The mechanism hypothesized
899		included the modification of the gut microbiota with the concomitant
900		reduction of serum LPS.
901	4.	Inflammation biomarkers, specifically serum LPS was decreased. It was
902		hypothesized that an increase in the butyrate-producing bacteria and
903		Bifidobacteria were instrumental in the reduction of the inflammatory
904		biomarkers.
905	5.	Based on the presumed mode of action, that is reducing inflammation by
906		lowering LPS and increasing production of butyrate, it is anticipated that this
907		formulation might be effective in relieving the signs and symptoms of other
908		inflammatory-based intestinal dysbioses.
909	In con	clusion, Sugar Shift in this study, was shown to be a suitable nutritional
910	supple	ement for the control of T2DM and the reduction of biomarkers associated with
911	this dy	ysbiosis

913 Acknowledgments

- 914 We would like to express our gratitude to Dr. Miguel H. Estévez del Toro, Director of
- 915 the Hermanos Ameijeiras Hospital and to Yurailis Reyes, Eng. For their support in
- 916 initiating and conducting the study.
- 917
- 918 This work was supported by The BioCollective, LLC.
- 919

920 References Cited

921	1.	Sharma S, Tripathi P. Gut microbiome and type 2 diabetes: where we are and
922		where to go? The Journal of Nutritional Biochemistry. 2019;63:101-8.
923	2.	Corrigendum to: 2019 ESC Guidelines on diabetes, pre-diabetes, and
924		cardiovascular diseases developed in collaboration with the EASD. Eur Heart
925		J [Internet]. 2020 Dec 1; 41(45):[4317 p.].
926	3.	MINSAP. Anuario Estadístico de Salud2019
927	4.	Singer-Englar T, Barlow G, Mathur R. Obesity, diabetes, and the gut
928		microbiome: an updated review. Expert Review of Gastroenterology &
929		Hepatology. 2019;13(1):3-15.
930	5.	Xourgia E, Papazafiropoulou A, Papanas N, Melidonis A. Anti-diabetic
931		treatment leads to changes in gut microbiome. Frontiers in bioscience
932		(Landmark edition). 2019;24(4):688-99.
933	6.	Mailing LJ, Allen JM, Buford TW, Fields CJ, Woods JA. Exercise and the Gut
934		Microbiome: A Review of the Evidence, Potential Mechanisms, and
935		Implications for Human Health. Exercise and Sport Sciences Reviews.
936		2019;47(2).
937	7.	Merkevičius K, Kundelis R, Maleckas A, Veličkienė D. Microbiome Changes
938		after Type 2 Diabetes Treatment: A Systematic Review. 2021;57(10):1084.

939	8.	Chatterjee S, Khunti K, Davies MJ. Type 2 diabetes. The lancet.
940		2017;389(10085):2239-51.
941	9.	Scheen AJ. Pathophysiology of type 2 diabetes. Acta Clinica Belgica.
942		2003;58(6):335-41.
943	10.	Milardi D, Gazit E, Radford SE, Xu Y, Gallardo RU, Caflisch A, et al.
944		Proteostasis of islet amyloid polypeptide: A molecular perspective of risk
945		factors and protective strategies for type II diabetes. Chemical Reviews.
946		2021;121(3):1845-93.
947	11.	Kumari R, Sanjukta S, Sahoo D, Rai AK. Functional peptides in Asian protein
948		rich fermented foods: production and health benefits. Systems Microbiology
949		and Biomanufacturing. 2021:1-13.
950	12.	Kumari R, Yadav Y, Misra R, Das U, Adhikari UD, Malakar P, et al. Emerging
951		frontiers of antibiotics use and their impacts on the human gut microbiome.
952		Microbiological Research. 2022:127127.
953	13.	Bellary S, Kyrou I, Brown JE, Bailey CJ. Type 2 diabetes mellitus in older
954		adults: clinical considerations and management. Nature Reviews
955		Endocrinology. 2021;17(9):534-48.
956	14.	Jonas W, Schürmann A. Genetic and epigenetic factors determining NAFLD
957		risk. Molecular Metabolism. 2021;50:101111.

Effect of Sugar Shift on the management of T2DM

958	15.	Arora A, Behl T, Sehgal A, Singh S, Sharma N, Bhatia S, et al. Unravelling the
959		involvement of gut microbiota in type 2 diabetes mellitus. Life sciences.
960		2021;273:119311.

961 16. Corb Aron RA, Abid A, Vesa CM, Nechifor AC, Behl T, Ghitea TC, et al.

962 Recognizing the Benefits of Pre-/Probiotics in Metabolic Syndrome and Type
963 2 Diabetes Mellitus Considering the Influence of Akkermansia muciniphila as a
964 Key Gut Bacterium. Microorganisms. 2021;9(3).

965 17. Rodrigues RR, Gurung M, Li Z, García-Jaramillo M, Greer R, Gaulke C, et al.
966 Transkingdom interactions between Lactobacilli and hepatic mitochondria
967 attenuate western diet-induced diabetes. Nature communications.
968 2021;12(1):1-15.

969 18. De Bernardini N, Basile A, Zampieri G, Kovalovszki A, De Diego Diaz B, Offer

970 E, et al. Integrating metagenomic binning with flux balance analysis to unravel

971 syntrophies in anaerobic CO2 methanation. Microbiome. 2022;10(1):1-18.

972 19. Colarusso AV, Goodchild-Michelman I, Rayle M, Zomorrodi AR.

973 Computational modeling of metabolism in microbial communities on a

genome-scale. Current Opinion in Systems Biology. 2021;26:46-57.

975 20. Calin MR KS, Sangwan N, Cano RJ. (Inventors) inventorProbiotics and976 Methods of use. USA2019.

977 21. Circu ML, Aw TY. Redox biology of the intestine. Free Radic Res. 2011;45(11-978 12):1245-66.

- 979 22. Cañete R. The Cuban Public Health System Focuses Research on Community
 980 Needs. Current Therapeutic Research. 2017;85:1.
- 981 23. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. The
 982 Journal of clinical investigation. 2006;116(7):1793-801.
- 983 24. Li H-Y, Zhou D-D, Gan R-Y, Huang S-Y, Zhao C-N, Shang A, et al. Effects
- and mechanisms of probiotics, prebiotics, synbiotics, and postbiotics on
 metabolic diseases targeting gut microbiota: a narrative review. Nutrients.
 2021;13(9):3211.
- 987 25. World Medical A. Declaration of Helsinki–Ethical Principles for Medical
 988 Research Involving Human Subjects [Internet]; 2018. 2021.
- 989 26. Petersmann A, Müller-Wieland D, Müller UA, Landgraf R, Nauck M,
- 990 Freckmann G, et al. Definition, Classification and Diagnosis of Diabetes
- 991 Mellitus. Exp Clin Endocrinol Diabetes [Internet]. 2019 20.12.2019; 127(S
- 992 01):[S1-S7 pp.].
- 993 27. Yoon S-H, Ha S-M, Kwon S, Lim J, Kim Y, Seo H, et al. Introducing
- 994 EzBioCloud: a taxonomically united database of 16S rRNA gene sequences
- and whole-genome assemblies. International journal of systematic and
- evolutionary microbiology. 2017;67(5):1613.

997	28.	Lee B, Moon T, Yoon S, Weissman T. DUDE-Seq: fast, flexible, and robust
998		denoising for targeted amplicon sequencing. PloS one. 2017;12(7):e0181463.
999	29.	Edgar RC, Haas BJ, Clemente JC, Quince C, Knight R. UCHIME improves
1000		sensitivity and speed of chimera detection. Bioinformatics. 2011;27(16):2194-
1001		200.
1002	30.	Edgar R. Usearch. Lawrence Berkeley National Lab.(LBNL), Berkeley, CA
1003		(United States); 2010.
1004	31.	Edgar RC. UPARSE: highly accurate OTU sequences from microbial amplicon
1005		reads. Nature methods. 2013;10(10):996-8.
1006	32.	Prasad DV, Madhusudanan S, Jaganathan S. uCLUST-a new algorithm for
1007		clustering unstructured data. ARPN Journal of Engineering and Applied
1008		Sciences. 2015;10(5):2108-17.
1009	33.	Douglas GM, Maffei VJ, Zaneveld JR, Yurgel SN, Brown JR, Taylor CM, et al.
1010		PICRUSt2 for prediction of metagenome functions. Nature biotechnology.
1011		2020;38(6):685-8.
1012	34.	Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes.
1013		Nucleic acids research. 2000;28(1):27-30.
1014	35.	Mann HB, Whitney DR. On a test of whether one of two random variables is
1015		stochastically larger than the other. The annals of mathematical statistics.
1016		1947:50-60.

1018		Wisconsin. Ecological Monographs (27). PRIMER-E Plymouth; 1957. p. 325-	-
1019		49.	
1020	37.	Lozupone CA, Stombaugh JI, Gordon JI, Jansson JK, Knight RJN. Diversity	,
1021		stability and resilience of the human gut microbiota. 2012;489(7415):220-30	
1022	38.	Anderson MJ. A new method for non-parametric multivariate analysis of	
1023		variance. Austral ecology. 2001;26(1):32-46.	
1024	39.	Daniel WW. Kruskal-Wallis one-way analysis of variance by ranks. Applied	
1025		nonparametric statistics. 1990:226-34.	
1026	40.	Segata N, Izard J, Waldron L, Gevers D, Miropolsky L, Garrett WS, et al.	
1027		Metagenomic biomarker discovery and explanation. Genome biology.	
1028		2011;12(6):1-18.	
1029	41.	Segata N, Waldron L, Ballarini A, Narasimhan V, Jousson O, Huttenhower C	•
1030		Metagenomic microbial community profiling using unique clade-specific	
1031		marker genes. Nature methods. 2012;9(8):811-4.	
1032	42.	Massey Jr FJJJotAsA. The Kolmogorov-Smirnov test for goodness of fit.	
1033		1951;46(253):68-78.	
1034	43.	F.R.S. KPJPMS. X. On the criterion that a given system of deviations from the	ıe
1035		probable in the case of a correlated system of variables is such that it can b	е
1036		reasonably supposed to have arisen from random sampling. 2009;50:157-7	5.
	Effect o	f Sugar Shift on the management of T2DM	54

Bray JR, Curtis JT. An ordination of upland forest communities of southern

1017

36.

1037	44.	Student. The probable error of a mean. Biometrika. 1908:1-25.
1038	45.	Friedman MJJotasa. The use of ranks to avoid the assumption of normality
1039		implicit in the analysis of variance. 1937;32(200):675-701.
1040	46.	Rosner B, Glynn RJ, Lee MLTJB. The Wilcoxon signed rank test for paired
1041		comparisons of clustered data. 2006;62(1):185-92.
1042	47.	Jones DH. Book Review: Statistical Methods, 8th Edition George W.
1043		Snedecor and William G. Cochran Ames: Iowa State University Press, 1989.
1044		xix + 491 pp. 1994;19(3):304-7.
1045	48.	Wickens TD, Keppel G. Design and analysis: A researcher's handbook:
1046		Pearson Prentice-Hall Upper Saddle River, NJ; 2004.
1047	49.	Shannon CE. A mathematical theory of communication. ACM SIGMOBILE
1048		mobile computing and communications review. 2001;5(1):3-55.
1049	50.	Chao A. Nonparametric estimation of the number of classes in a population.
1050		Scandinavian Journal of statistics. 1984:265-70.
1051	51.	Good IJ. The population frequencies of species and the estimation of
1052		population parameters. Biometrika. 1953;40(3-4):237-64.
1053	52.	Cox MAA, Cox TF. Multidimensional scaling. Handbook of data visualization:
1054		Springer; 2008. p. 315-47.

1055	53.	Jaccard P. Étude comparative de la distribution florale dans une portion des
1056		Alpes et des Jura. Bull Soc Vaudoise Sci Nat. 1901;37:547-79.
1057	54.	Fukunaga K. Introduction to statistical pattern recognition: Elsevier; 2013.
1058	55.	Robertson DS, Wildenhain J, Javanmard A, Karp NA. onlineFDR: an R
1059		package to control the false discovery rate for growing data repositories.
1060		Bioinformatics. 2019;35(20):4196-9.
1061	56.	Bostom AG, Kronenberg F, Ritz E. Predictive performance of renal function
1062		equations for patients with chronic kidney disease and normal serum
1063		creatinine levels. Journal of the American Society of Nephrology.
1064		2002;13(8):2140-4.
1065	57.	Finney H, Newman DJ, Price CP. Adult reference ranges for serum cystatin C,
1066		creatinine and predicted creatinine clearance. Annals of clinical biochemistry.
1067		2000;37(1):49-59.
1068	58.	Thiagarajan P, Parker CJ, Prchal JT. How do red blood cells die? Frontiers in
1069		Physiology. 2021;12:655393.
1070	59.	Pearson K. X. On the criterion that a given system of deviations from the
1071		probable in the case of a correlated system of variables is such that it can be
1072		reasonably supposed to have arisen from random sampling. The London,
1073		Edinburgh, and Dublin Philosophical Magazine and Journal of Science.
1074		1900;50(302):157-75.

1075	60.	Andrews S. FastQC: a quality control tool for high throughput sequence data
1076		Babraham Bioinformatics, Babraham Institute, Cambridge, United Kingdom;
1077		2010.

1078 61. Rosner B, Glynn RJ, Lee MLT. The Wilcoxon signed rank test for paired 1079 comparisons of clustered data. Biometrics. 2006;62(1):185-92.

1080 62. Sokal RR. A statistical method for evaluating systematic relationships. Univ1081 Kansas, Sci Bull. 1958;38:1409-38.

1082 63. Yin Y, Wang J. Predictive functional profiling of microbial communities in

1083 fermentative hydrogen production system using PICRUSt. International
1084 Journal of Hydrogen Energy. 2021;46(5):3716-25.

1085 64. Langille MGI, Zaneveld J, Caporaso JG, McDonald D, Knights D, Reyes JA, et

1086 al. Predictive functional profiling of microbial communities using 16S rRNA

1087 marker gene sequences. Nature biotechnology. 2013;31(9):814-21.

1088 65. Kocsis T, Molnár B, Németh D, Hegyi P, Szakács Z, Bálint A, et al. Probiotics

1089 have beneficial metabolic effects in patients with type 2 diabetes mellitus: a

1090 meta-analysis of randomized clinical trials. Scientific Reports.

1091 2020;10(1):11787.

Hu Y-m, Zhou F, Yuan Y, Xu Y-c. Effects of probiotics supplement in patients
with type 2 diabetes mellitus: A meta-analysis of randomized trials. Medicina
Clínica (English Edition). 2017;148(8):362-70.

1095 67. Asemi Z, Zare Z, Shakeri H, Sabihi S-s, Esmailizaden AJAon, me

- 1096 Effect of multispecies probiotic supplements on metabolic profiles, hs-CRP,
 1097 and oxidative stress in patients with type 2 diabetes. 2013;63(1-2):1-9.
- 1098 68. Mohammad-Shahi M, Veissi M, Haidari F, Shahbazian H, Kaydani G-A,
- 1099 Mohammadi F. Effects of probiotic yogurt consumption on inflammatory
- biomarkers in patients with type 2 diabetes2014 2014/6/30 %J Bioimpacts;
- 1101 4(2):[83-8 pp.]. Available from:
- 1102 <u>https://bi.tbzmed.ac.ir/Article/BI_1211_20131009200630</u>.
- 1103 69. Firouzi S, Majid HA, Ismail A, Kamaruddin NA, Barakatun-Nisak M-YJEjon.
- 1104 Effect of multi-strain probiotics (multi-strain microbial cell preparation) on
- 1105 glycemic control and other diabetes-related outcomes in people with type 2
- 1106 diabetes: a randomized controlled trial. 2017;56(4):1535-50.
- 1107 70. Hove KD, Brøns C, Færch K, Lund SS, Rossing P, Vaag A. Effects of 12
- 1108 weeks of treatment with fermented milk on blood pressure, glucose
- 1109 metabolism and markers of cardiovascular risk in patients with type 2
- 1110 diabetes: a randomised double-blind placebo-controlled study. European
- 1111 Journal of Endocrinology. 2015;172(1):11-20.
- 1112 71. Asemi Z, Alizadeh S-A, Ahmad K, Goli M, Esmaillzadeh AJCN. Effects of beta-
- 1113 carotene fortified synbiotic food on metabolic control of patients with type 2
- 1114 diabetes mellitus: A double-blind randomized cross-over controlled clinical
- 1115 trial. 2016;35(4):819-25.

1116	72.	American Diabetes A. 2. Classification and diagnosis of diabetes: standards
1117		of medical care in diabetes-2021. Diabetes care. 2021;44(Supplement
1118		1):S15-S33.
1119	73.	Cohen RM, Franco RS, Khera PK, Smith EP, Lindsell CJ, Ciraolo PJ, et al.
1120		Red cell life span heterogeneity in hematologically normal people is sufficient
1121		to alter HbA1c. Blood, The Journal of the American Society of Hematology.
1122		2008;112(10):4284-91.
1123	74.	Lew VL, Tiffert T. On the Mechanism of Human Red Blood Cell Longevity:
1124		Roles of Calcium, the Sodium Pump, PIEZO1, and Gardos Channels. (1664-
1125		042X (Print)).
1126	75.	Scheen AJ. Metformin and COVID-19: From cellular mechanisms to reduced
1127		mortality. Diabetes & Metabolism. 2020;46(6):423-6.
1128	76.	Hamer M, Gale CR, Batty GD. Diabetes, glycaemic control, and risk of
1129		COVID-19 hospitalisation: Population-based, prospective cohort study.
1130		Metabolism. 2020;112:154344.
1131	77.	Caycho-Rodríguez T, Vilca LW, Corrales-Reyes IE, Hernández-García F,
1132		Pérez AP, Quintana PG, et al. COVID-19 contagion concern scale (PRE-
1133		COVID-19): Validation in Cuban patients with type 2 diabetes. Diabetes &
1134		Metabolic Syndrome: Clinical Research & Reviews. 2021;15(5):102245.
1135	78.	Rice JA. Mathematical statistics and data analysis: Cengage Learning; 2006.

1136	79.	Isolauri E, Sütas Y, Kankaanpää P, Arvilommi H, Salminen S. Probiotics:
1137		effects on immunity. The American Journal of Clinical Nutrition.
1138		2001;73(2):444s-50s.
1139	80.	Maldonado Galdeano C, Cazorla SI, Lemme Dumit JM, Vélez E, Perdigón G.
1140		Beneficial Effects of Probiotic Consumption on the Immune System. Annals of
1141		Nutrition and Metabolism. 2019;74(2):115-24.
1142	81.	Sato J, Kanazawa A, Azuma K, Ikeda F, Goto H, Komiya K, et al. Probiotic
1143		reduces bacterial translocation in type 2 diabetes mellitus: A randomised
1144		controlled study. 2017;7(1):1-10.
1145	82.	Madempudi RS, Ahire JJ, Neelamraju J, Tripathi A, Nanal S. Efficacy of
1146		UB0316, a multi-strain probiotic formulation in patients with type 2 diabetes
1147		mellitus: A double blind, randomized, placebo controlled study. PLOS ONE.
1148		2019;14(11):e0225168.
1149	83.	Nesti L, Mengozzi A, Tricò D. Impact of nutrient type and sequence on
1150		glucose tolerance: physiological insights and therapeutic implications.
1151		Frontiers in Endocrinology. 2019;10:144.
1152	84.	Dimitriadis GD, Maratou E, Kountouri A, Board M, Lambadiari V. Regulation of
1153		postabsorptive and postprandial glucose metabolism by insulin-dependent
1154		and insulin-independent mechanisms: an integrative approach. Nutrients.
1155		2021;13(1):159.

1156	85.	Gérard C, Vidal H. Impact of gut microbiota on host glycemic control.
1157		Frontiers in endocrinology. 2019;10:29.
1158	86.	Carlin MR, Kazemi,S.K., Sangwan,N., Cano,R.J., inventorProbiotics and
1159		Methos of Use. USA patent WO2019/113023A9. 2019 05.12.2019
1160	87.	Salvi PS, Cowles RA. Butyrate and the Intestinal Epithelium: Modulation of
1161		Proliferation and Inflammation in Homeostasis and Disease. LID -
1162		10.3390/cells10071775 [doi] LID - 1775. (2073-4409 (Electronic)).
1163	88.	Sivamaruthi BS, Fern LA, Rashidah Pg Hj Ismail DSN, Chaiyasut C. The
1164		influence of probiotics on bile acids in diseases and aging. Biomedicine &
1165		Pharmacotherapy. 2020;128:110310.
1166	89.	Liong MT, Shah NP. Acid and Bile Tolerance and Cholesterol Removal Ability
1167		of Lactobacilli Strains. Journal of Dairy Science. 2005;88(1):55-66.
1168	90.	Lye HS, Rusul G, Liong MT. Removal of cholesterol by lactobacilli via
1169		incorporation and conversion to coprostanol. Journal of Dairy Science.
1170		2010;93(4):1383-92.
1171	91.	Wang C, Li S, Xue P, Yu L, Tian F, Zhao J, et al. The effect of probiotic
1172		supplementation on lipid profiles in adults with overweight or obesity: A meta-
1173		analysis of randomized controlled trials. Journal of Functional Foods.
1174		2021;86:104711.

1175	92.	Salamone D, Rivellese AA, Vetrani C. The relationship between gut
1176		microbiota, short-chain fatty acids and type 2 diabetes mellitus: the possible
1177		role of dietary fibre. Acta Diabetologica. 2021;58(9):1131-8.
1178	93.	Chomani S. The effect of exercise training at different intensities on blood
1179		glucose regulation and cardiorespiratory fitness in patients with Type 2
1180		Diabetes: a randomized controlled trial. VIREF Revista de Educación Física.
1181		2021;10(4):148-57.
1182	94.	Kim YA, Keogh JB, Clifton PM. Probiotics, prebiotics, synbiotics and insulin
1183		sensitivity. Nutrition Research Reviews. 2018;31(1):35-51.
1184	95.	Chen Z, Radjabzadeh D, Chen L, Kurilshikov A, Kavousi M, Ahmadizar F, et
1185		al. Association of insulin resistance and type 2 diabetes with gut microbial
1186		diversity: a microbiome-wide analysis from population studies.
1187		2021;4(7):e2118811-e.
1188	96.	Petersen MC, Shulman GI. Mechanisms of Insulin Action and Insulin
1189		Resistance. 2018;98(4):2133-223.
1190	97.	Sesti G. Pathophysiology of insulin resistance. Best practice & research
1191		Clinical endocrinology & metabolism. 2006;20(4):665-79.
1192	98.	Samuel VT, Shulman GI. The pathogenesis of insulin resistance: integrating
1193		signaling pathways and substrate flux. The Journal of clinical investigation.
1194		2016;126(1):12-22.

1195	99.	Chen L, Chen R, Wang H, Liang F. Mechanisms linking inflammation to insulin
1196		resistance. International journal of endocrinology. 2015;2015.
1197	100.	Jang HR, Lee H-YJWJoD. Mechanisms linking gut microbial metabolites to
1198		insulin resistance. 2021;12(6):730.
1199	101.	Schertzer JD, Lam TKJAJoP-E, Metabolism. Peripheral and central regulation
1200		of insulin by the intestine and microbiome. American Physiological Society
1201		Rockville, MD; 2021. p. E234-E9.
1202	102.	Chen Z, Radjabzadeh D, Chen L, Kurilshikov A, Kavousi M, Ahmadizar F, et
1203		al. Association of Insulin Resistance and Type 2 Diabetes With Gut Microbial
1204		Diversity: A Microbiome-Wide Analysis From Population Studies. (2574-3805
1205		(Electronic)).
1206	103.	Zouiouich S, Loftfield E, Huybrechts I, Viallon V, Louca P, Vogtmann E, et al.
1207		Markers of metabolic health and gut microbiome diversity: findings from two
1208		population-based cohort studies. Diabetologia. 2021;64(8):1749-59.
1209	104.	Salguero MV, Al-Obaide MAI, Singh R, Siepmann T, Vasylyeva TL. Dysbiosis
1210		of Gram-negative gut microbiota and the associated serum
1211		lipopolysaccharide exacerbates inflammation in type 2 diabetic patients with
1212		chronic kidney disease. Experimental and therapeutic medicine.
1213		2019;18(5):3461-9.

1214	105.	Cani PD, Osto M, Geurts L, Everard A. Involvement of gut microbiota in the
1215		development of low-grade inflammation and type 2 diabetes associated with
1216		obesity. Gut microbes. 2012;3(4):279-88.
1217	106.	Snelson M, de Pasquale C, Ekinci El, Coughlan MT. Gut microbiome,
1218		prebiotics, intestinal permeability and diabetes complications. Best Practice &
1219		Research Clinical Endocrinology & Metabolism. 2021;35(3):101507.
1220	107.	Candelli M, Franza L, Pignataro G, Ojetti V, Covino M, Piccioni A, et al.
1221		Interaction between Lipopolysaccharide and Gut Microbiota in Inflammatory
1222		Bowel Diseases. International Journal of Molecular Sciences [Internet]. 2021;
1223		22(12).
1224	108.	Turnbaugh PJ, Ley RE, Hamady M, Fraser-Liggett CM, Knight R, Gordon JI.
1225		The Human Microbiome Project. Nature. 2007;449(7164):804-10.
1226	109.	Proctor LM, Creasy HH, Fettweis JM, Lloyd-Price J, Mahurkar A, Zhou W, et
1227		al. The Integrative Human Microbiome Project. Nature. 2019;569(7758):641-8.
1228	110.	Ehrlich SD, Meta HITC. MetaHIT: The European Union Project on
1229		metagenomics of the human intestinal tract. Metagenomics of the human
1230		body: Springer; 2011. p. 307-16.
1231	111.	Vacca M, Celano G, Calabrese FM, Portincasa P, Gobbetti M, De Angelis M.
1232		The Controversial Role of Human Gut Lachnospiraceae. 2020;8(4):573.

Effect of Sugar Shift on the management of T2DM

1233	112.	Gao J, Guo X, Wei W, Li R, Hu K, Liu X, et al. The association of fried meat
1234		consumption with the gut microbiota and fecal metabolites and its impact on
1235		glucose homoeostasis, intestinal endotoxin levels, and systemic inflammation:
1236		a randomized controlled-feeding trial. Diabetes Care. 2021;44(9):1970-9.
1237	113.	Esgalhado M, Kemp JA, Damasceno NR, Fouque D, Mafra DJFm. Short-chain
1238		fatty acids: A link between prebiotics and microbiota in chronic kidney
1239		disease. 2017;12(15):1413-25.
1240	114.	Sun M, Wu W, Liu Z, Cong YJJog. Microbiota metabolite short chain fatty
1241		acids, GPCR, and inflammatory bowel diseases. 2017;52(1):1-8.
1242	115.	Portune KJ, Benítez-Páez A, Del Pulgar EMG, Cerrudo V, Sanz YJMn,
1243		research f. Gut microbiota, diet, and obesity-related disorders-The good, the
1244		bad, and the future challenges. 2017;61(1):1600252.
1245	116.	Orsso CE, Peng Y, Deehan EC, Tan Q, Field CJ, Madsen KL, et al.
1246		Composition and Functions of the Gut Microbiome in Pediatric Obesity:
1247		Relationships with Markers of Insulin Resistance. 2021;9(7):1490.
1248	117.	Gurung M, Li Z, You H, Rodrigues R, Jump DB, Morgun A, et al. Role of gut
1249		microbiota in type 2 diabetes pathophysiology. (2352-3964 (Electronic)).
1250	118.	Qian XA-O, Si Q, Lin G, Zhu M, Lu J, Zhang H, et al. Bifidobacterium
1251		adolescentis Is Effective in Relieving Type 2 Diabetes and May Be Related to

1252		Its Dominant Core Genome and Gut Microbiota Modulation Capacity. LID -
1253		10.3390/nu14122479 [doi] LID - 2479. (2072-6643 (Electronic)).
1254	119.	Laursen MA-O, Laursen RP, Larnkjær A, Mølgaard C, Michaelsen KF, Frøkiær
1255		H, et al. Faecalibacterium Gut Colonization Is Accelerated by Presence of
1256		Older Siblings. LID - 10.1128/mSphere.00448-17 [doi] LID - e00448-17.
1257		(2379-5042 (Print)).
1258	120.	Parsaei M, Sarafraz N, Moaddab SY, Ebrahimzadeh Leylabadlo H. The
1259		importance of Faecalibacterium prausnitzii in human health and diseases.
1260		(2052-2975 (Print)).
1261	121.	Sokol H, Pigneur B, Watterlot L, Lakhdari O, Bermúdez-Humarán LG,
1262		Gratadoux J-J, et al. Faecalibacterium prausnitzii is an anti-inflammatory
1263		commensal bacterium identified by gut microbiota analysis of Crohn disease
1264		patients. Proceedings of the National Academy of Sciences.
1265		2008;105(43):16731-6.
	100	Zhang S. Zhao, I. Xie F. He H. Johnston I. J. Dai X. et al. Dietany fiber-derived
1266	122.	Zhang S, Zhao S, Ale F, He H, Sonnston LS, Dai A, et al. Dietary liber-derived
1266 1267	122.	short-chain fatty acids: A potential therapeutic target to alleviate
1266 1267 1268	122.	short-chain fatty acids: A potential therapeutic target to alleviate obesity-related nonalcoholic fatty liver disease. Obesity Reviews.

1270	123.	Liu J, Li Q, Yang Y, Ma L. Iron metabolism and type 2 diabetes mellitus: A
1271		meta-analysis and systematic review. Journal of diabetes investigation.
1272		2020;11(4):946-55.

- 1273 124. Fernández-Real JM, McClain D, Manco M. Mechanisms linking glucose
 1274 homeostasis and iron metabolism toward the onset and progression of type 2
 1275 diabetes. Diabetes care. 2015;38(11):2169-76.
- 1276 125. Cartron ML, Maddocks S, Gillingham P, Craven CJ, Andrews SC. Feo -
- 1277 Transport of Ferrous Iron into Bacteria. Biometals. 2006;19(2):143-57.
- 1278 126. Mayneris-Perxachs J, Moreno-Navarrete JM, Fernández-Real JM. The role of
- 1279 iron in host-microbiota crosstalk and its effects on systemic glucose

1280 metabolism. Nature Reviews Endocrinology. 2022.

- 1281 127. Ruggles KV, Turkish A, Sturley SLJAron. Making, baking, and breaking: the 1282 synthesis, storage, and hydrolysis of neutral lipids. 2013:413-51.
- 1283 128. Liu T, Chen X, Xu Y, Wu W, Tang W, Chen Z, et al. Gut microbiota partially

1284 mediates the effects of fine particulate matter on type 2 diabetes: Evidence

- 1285 from a population-based epidemiological study. Environment International.
- 1286 2019;130:104882.
- 1287 129. Maskarinec G, Raquinio P, Kristal BS, Setiawan VW, Wilkens LR, Franke AA,
- 1288 et al. The gut microbiome and type 2 diabetes status in the Multiethnic
- 1289 Cohort. Plos one. 2021;16(6):e0250855.



CONSORT 2010 Flow Diagram





Figure 1

BiotiQuest[™] Sugar Shift Clinical Study Design

	-//	0	1	2	3	4	5	6	7	8	9	10	11		12	-	+//+
Enr	ollment					Clinic	al St	udy	(12 w	eeks)						Ana	alysis
	Visit	1 – Da	ay 1		Visit	y 28		Vis	Visit 3 – Day 56			Vi	isit 4 ·	– Day	Day 84		
	BMI (Body Fasting glue Postprandia Hemoglobin Lipid profile Creatinine Serum LPS Fecal samp		Index cose 2h		BMI (Bod Fasting g Postprand	y Mass lucose dial gluc	Index :ose 2h		BMI (Be Fasting Postpra	ody Mass glucose indial glu	Index	1	BMI (Fastir Postp Hemo Lipid Creat Serun Fecal	Body ng gluo randia oglobir profile inine n LPS samp	Mass I cose al gluco n A1c	ndex ose 2h	

Figure 2

-



Figure 3



Figure 4


Figure 5



Figure 6